Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 300
- 主要终点
- Immuno-inflammatory profile description in patients with ischemic stroke and eligible for reperfusion treatment
研究概览
简要总结
IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different parameters over time. Post-hoc analyses will make it possible to correlate the immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical outcome in terms of post-AIC functional and cognitive disability.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presenting an ISCHEMIC STROKE for which reperfusion treatment is indicated according to European and North American recommendations (intraveinous thrombolysis or mechanical thrombectomy or a combination of both)
排除标准
- •Contraindication to performing a cerebral MRI (claustrophobia, pacemaker or other implantable device contraindicating the performance of MRI)
- •Intracranial haemorrhage associated with AIC on initial imaging
- •Immunosuppressive treatment or corticosteroid therapy on admission of the patient
- •Pre-existing neurological disability limiting the neurological assessment to 3 months (mRS>2 on admission)
- •Dementia known and diagnosed pre-existing at ischemic stroke
- •Absolute or relative contraindication to gadolinium injection (history of true allergic reaction or intolerance to gadobutrol, renal failure with creatinine clearance <15mL/min, pregnant or breastfeeding woman).
研究组 & 干预措施
Immuno-inflammatory profile description in patients with ischemic stroke
Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
干预措施: Immuno-inflammatory profile description in patients with ischemic stroke (Other)
结局指标
主要结局
Immuno-inflammatory profile description in patients with ischemic stroke and eligible for reperfusion treatment
时间窗: Up to year
Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA preconfigurated panels for inflammatory biomarkers.
次要结局
未报告次要终点